Familial cases of pseudohypoaldosteronism type II harboring a novel mutation in the Cullin 3 gene.


Journal

Nephrology (Carlton, Vic.)
ISSN: 1440-1797
Titre abrégé: Nephrology (Carlton)
Pays: Australia
ID NLM: 9615568

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 05 04 2020
revised: 07 06 2020
accepted: 19 06 2020
pubmed: 4 7 2020
medline: 30 10 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

Pseudohypoaldosteronism type II (PHA II) is inherited in an autosomal dominant manner and is characterized by hypertension, hyperkalemia, and hyperchloremic metabolic acidosis. The enhancement of with-no-lysine kinase (WNK) functions is correlated to the pathogenesis of the condition. Cullin 3 (CUL3) forms an E3 ubiquitin ligase complex, and it can ubiquitinate WNK. Most CUL3 gene mutations are distributed in sites, such as intron 8 splice acceptor, intron 9 splice donor, and putative intron 8 splice branch sites, which are involved in the splicing of exon 9. These mutations result in the deletion of exon 9, which reduces the activity of ubiquitination against WNK and inhibits the degradation of WNK. In this report, we identified a novel CUL3 c.1312A>G mutation in familial cases. A mutation prediction software showed that the significance of these mutations was not clear. However, using the Human Splicing Finder 3.1 software, in silico analyses revealed that these mutations induced splicing alterations, which affected the sites of exon 9, altered the balance between predicted exonic splicing enhancers and silencers, and led to the deletions of exon 9. This study presented a novel pathogenic splicing variant to the CUL3 mutation and provided a reference for further research about the mechanisms of splicing. Moreover, it showed that not only amino acid substitution caused by nonsynonymous mutations but also splicing motif changes due to base substitutions have important roles in the pathogenesis of PHA II.

Identifiants

pubmed: 32619053
doi: 10.1111/nep.13752
doi:

Substances chimiques

CUL3 protein, human 0
Cullin Proteins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

818-821

Informations de copyright

© 2020 Asian Pacific Society of Nephrology.

Références

McCormick JA, Yang CL, Zhang C, et al. Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3. J Clin Invest. 2014;124:4723-4736.
Ohta A, Schumacher FR, Mehellou Y, et al. The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. Biochem J. 2013;451:111-122.
Shibata S, Zhang J, Puthumana J, Stone KL, Lifton RP. Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. Proc Natl Acad Sci. 2013;110:7838-7843.
Boyden LM, Choi M, Choate KA, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012;482:98-102.
Shao L, Cui L, Lu J, Lang Y, Bottillo I, Zhao X. A novel mutation in exon 9 of Cullin 3 gene contributes to aberrant splicing in pseudohypoaldosteronism type II. FEBS Open Biol. 2018;8:461-469.
Schneider, CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature Methods. 2012;9:671-675.

Auteurs

Kiyoshi Nakano (K)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.

Yasuo Kubota (Y)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.
Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Takayuki Mori (T)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.
Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Motoko Chiga (M)

Department of Nephrology, Tokyo Medical and Dental University, Tokyo, Japan.

Takayasu Mori (T)

Department of Nephrology, Tokyo Medical and Dental University, Tokyo, Japan.

Shyunya Sonoda (S)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.

Daisuke Ueda (D)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.

Isao Asakura (I)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.

Takeshi Ikegaya (T)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.

Jiro Kagawa (J)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.

Shinichi Uchida (S)

Department of Nephrology, Tokyo Medical and Dental University, Tokyo, Japan.

Akira Kubota (A)

Department of Pediatrics, Fujieda Municipal General Hospital, Fujieda, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH